Search results
Results from the WOW.Com Content Network
Toggle Antipsychotics subsection. 1.1 Antipsychotic esters. 1.1.1 Typical antipsychotics. ... Download as PDF; Printable version; In other projects Wikidata item ...
This is a list of psychiatric medications used by psychiatrists and other physicians to treat mental illness or distress.. The list is ordered alphabetically according to the condition or conditions, then by the generic name of each medication.
Atypical antipsychotics include: Aripiprazole (Abilify) – approved as an adjunct to antidepressant for major depression; Brexpiprazole (Rexulti) – approved as an adjunct to antidepressant for major depression; Lumateperone (Caplyta) – approved as an adjunct to mood stabilizer for bipolar depression
Lumateperone, sold under the brand name Caplyta, is an atypical antipsychotic medication of the butyrophenone class. It is approved for the treatment of schizophrenia as well as bipolar depression, as either monotherapy or adjunctive therapy (with lithium or valproate). [2] It is developed by Intra-Cellular Therapies, licensed from Bristol ...
In 2009, it was granted approval for the treatment of treatment-resistant depression. [ 4 ] Olanzapine/fluoxetine, or other antidepressant / antipsychotic combinations, are sometimes prescribed off-label for anxiety disorders , [ 5 ] eating disorders , [ 6 ] obsessive–compulsive disorder (OCD), [ 7 ] and posttraumatic stress disorder (PTSD).
Amisulpride is approved and used at low doses in the treatment of dysthymia and major depressive disorder. [10] [20] [11] [21] [22] [23] Whereas typical doses used in schizophrenia block postsynaptic dopamine D 2-like receptors and reduce dopaminergic neurotransmission, low doses of amisulpride preferentially block presynaptic dopamine D 2 and D 3 autoreceptors and thereby disinhibit dopamine ...
The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years. Cobenfy, manufactured by Bristol Myers Squibb ...
This is a list of investigational antidepressants, or drugs that are currently under development for clinical use in the treatment of depression but are not yet approved. Specific indications include major depressive disorder, treatment-resistant depression, dysthymia, bipolar depression, and postpartum depression, among others.